Topical Therapies in Seborrheic Dermatitis: Mechanisms and Limitations

In Topical Therapies in Seborrheic Dermatitis: Mechanisms and Limitations, our panel/experts delve(s) into the following critical questions:

Historically, SD has been managed with topical antifungals, corticosteroids, and keratolytic agents. How do these agents address immune and barrier dysregulation pathways seen in SD?

How well do they address inflammation versus symptom control in SD?

What limitations or unmet needs do you observe with steroid-based treatments especially for long-term or facial use in patients with SD?

Led by the moderator, the dermatologists discuss seborrheic dermatitis (SD) management with topical antifungals, corticosteroids, and keratolytic agents, each targeting different aspects of the disease. Antifungals reduce Malassezia colonization, indirectly decreasing inflammatory signaling and helping restore barrier homeostasis. Corticosteroids directly suppress local immune activation, reducing erythema and pruritus, but primarily offer symptomatic relief rather than addressing underlying triggers. Keratolytic agents, such as zinc pyrithione or salicylic acid, help remove scale and support barrier repair, which can also mitigate inflammation. While these therapies can be effective for short-term symptom control, they often do not fully resolve the immune dysregulation that drives chronic SD. Long-term or facial use of corticosteroids is limited by risks such as skin atrophy, telangiectasia, and rebound flares, making sustained management challenging. These limitations underscore the need for safer, targeted, and steroid-sparing treatments that can both control symptoms and modulate the underlying immune and barrier dysfunction in SD.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Our next episode, Non-Steroidal Therapies and Targeted Inflammation in Seborrheic Dermatitis, further explores the role of non-steroidal therapies in managing chronic inflammation and supporting long-term control of seborrheic dermatitis. It also explains how PDE-4 inhibition increases intracellular cAMP, modulating key inflammatory pathways to provide targeted, steroid-sparing treatment for SD.